Enhanced Oxygen Therapeutic for Solid Tumor Treatment

An improved system and method for treating solid tumors by combining fractionated radiotherapy and chemotherapy with an oxygen therapeutic to increase oxygen levels in the tumors, enhancing treatment effectiveness and safety.

The original patent disclosed a method for treating glioblastoma using fractionated radiotherapy and chemotherapy with an oxygen therapeutic. However, this approach has limitations, including the risk of hypoxia in solid tumors, which can reduce treatment effectiveness. The new inventive concept addresses these limitations by introducing a system and method that ensures consistent oxygen levels in solid tumors during treatment, enhancing treatment outcomes and reducing the risk of hypoxia.

The new inventive concept comprises a system with three modules: a radiation therapy module, a chemotherapy module, and an oxygen therapeutic module. The oxygen therapeutic module administers an oxygen therapeutic in a controlled release formulation to maintain a consistent oxygen level in the solid tumor during radiation therapy and chemotherapy. This approach ensures that the solid tumor is well-oxygenated, making it more susceptible to radiation therapy and chemotherapy. The system can be configured to administer the oxygen therapeutic through various routes, including intravenous infusion. The method of the inventive concept involves administering the oxygen therapeutic to a subject suffering from a solid tumor, followed by repeated administrations of radiation therapy and chemotherapy medications.

The new inventive concept introduces the use of a controlled release formulation for the oxygen therapeutic, ensuring consistent oxygen levels in solid tumors during treatment. This approach is novel and non-obvious compared to the original patent, which did not disclose such a formulation. The inventive concept also provides a system and method for treating solid tumors that is more effective and safer than the original patent.

Alternative embodiments of the inventive concept could include different routes of administration for the oxygen therapeutic, such as oral or topical administration. The system could also be modified to include additional modules, such as a module for monitoring oxygen levels in the solid tumor. Variations of the method could include adjusting the dosage and timing of the oxygen therapeutic administration based on the specific type and stage of the solid tumor.

The enhanced oxygen therapeutic system and method have significant commercial potential in the oncology market, particularly for the treatment of solid tumors. The inventive concept could be licensed to pharmaceutical companies or medical device manufacturers, or developed into a proprietary product by NuvOx Pharma LLC. The market potential is substantial, given the high incidence of solid tumors and the need for more effective and safer treatment options.